MetaCap

Helus Pharma (HELP) vs Monopar Therapeutics (MNPR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Helus Pharma (HELP) has outperformed Monopar Therapeutics (MNPR) over the past year, gaining 9.3% versus a loss of 24.6%. Over five years, MNPR leads with a +184.5% price change compared with -88.1% for HELP. Helus Pharma is the larger company by market cap ($487.7 million vs $467.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HELP+9.30%MNPR-24.64%
+161%+53%-55%
Nov 21, 20251 yearNov 20, 2026
HELP-90.14%MNPR+192.99%
+431%+156%-119%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HELP versus MNPR key metrics
MetricHELPMNPR
Share price$6.11$69.00
Market cap$487.68M$467.60M
1-day change-9.88%-1.84%
YTD return-25.31%+5.67%
1-year return+9.30%-24.64%
5-year return-88.09%+184.54%
EPS (TTM)$-4.25$-2.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)—$-13.72M
52-week high$15.15$124.82
52-week low$3.76$50.07
Distance from 52-week high-59.67%-44.72%
Analyst consensusnonestrong_buy
Avg. price target upside+564.81%+88.65%
Average volume1.83M151.83K
Shares outstanding79.81M6.78M
Employees10022
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HELP has outperformed MNPR by 33.9 percentage points over the past year.

About Helus Pharma

HELP stock →

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Monopar Therapeutics

MNPR stock →

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.

Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees

HELP vs MNPR FAQ

Which is bigger, Helus Pharma or Monopar Therapeutics?

Helus Pharma (HELP) is larger, with a market capitalization of $487.68M compared with $467.60M for Monopar Therapeutics (MNPR).

Which stock has performed better over the past year, HELP or MNPR?

HELP returned +9.30% over the past 12 months, compared with -24.64% for MNPR (price return, excluding dividends). Past performance does not predict future results.

Are Helus Pharma and Monopar Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons